Long-term effects of immunomodulatory treatments in Type 1 Diabetes

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study follows participants who previously took part in selected Type 1 Diabetes Mellitus studies involving immunomodulatory agents. It aims to assess how long these individuals continue to produce insulin and how changes in their immune system over time relate to insulin production. Participants may have follow-up visits ranging from one to five years, which will include health assessments, blood and urine collections, and mixed meal tolerance tests for certain individuals. The findings could inform the development of improved therapies for Type 1 Diabetes in the future.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Prior participant in an Immune Tolerance Network (ITN) executive committee approved T1DM study.
* Ability to sign informed consent/assent (as applicable for children).

Exclusion Criteria:

* Any medical condition that in the opinion of the principal investigator would interfere with safe completion of the trial; or
* Inability to comply with the study visit schedule and required assessments.

Where it's running

• UCSF School of Medicine
  San Francisco, California, United States Recruiting
• Stanford University
  Stanford, California, United States Recruiting
• University of Colorado School of Medicine: Barbara Davis Center for Diabetes
  Aurora, Colorado, United States Recruiting
• Indiana University Riley Hospital for Children
  Indianapolis, Indiana, United States Recruiting
• University of Iowa Health Care Division of Pediatric Endocrinology
  Iowa City, Iowa, United States Recruiting
• Joslin Diabetes Center
  Boston, Massachusetts, United States Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Near-sensor insulin delivery with CGM in people with type 1 diabetes

  A small early-feasibility study tests a dual-port insulin patch pump that includes a CGM sensor to see if delivering insulin near the sensor affects glucose readings and whether an automated control algorithm can manage glucose.

  Recruiting Early Phase 1 ClinSurge Research · Toronto, Ontario · NCT07655076

• Tirzepatide added to an automated insulin delivery system to help adults with type 1 diabetes manage blood sugar

  This study tests whether once-weekly tirzepatide can help adults with type 1 diabetes use their insulin pumps more easily, possibly reducing the need to count carbohydrates at meals.

  Recruiting Phase 2/3 McGill University Health Centre/Research Institute of the McGill University Health Centre · Montreal, Quebec and 3 other locations · NCT07284511

• CNP-103 treatment for adolescents and young adults recently diagnosed with stage 3 type 1 diabetes

  This trial will test whether multiple doses of CNP-103, compared with placebo, help people ages 12–35 who were diagnosed with stage 3 type 1 diabetes within the past 6 months.

  Recruiting at 45 sites Phase 1/2 COUR Pharmaceutical Development Company, Inc. · Tucson, Arizona and 44 other locations · NCT06783309

• Investigating the safety and effectiveness of porcine pancreatic cells in patients with Type 1 diabetes

  This study is testing if using pig pancreas cells can help adults with tough-to-manage Type 1 diabetes feel better and avoid dangerous low blood sugar episodes.

  Recruiting Phase 1/2 Otsuka Pharmaceutical Factory, Inc. · Chicago, Illinois · NCT06575426

• Pediatric Insulin Dose Calculator to Help Manage Type 1 Diabetes in Under-12s

  A digital tool that helps caregivers of children under 12 with Type 1 diabetes calculate insulin doses during meals, tested alongside standard care for 6 months.

  Recruiting at 2 sites Sultan Qaboos University · Mosul and 1 other locations · NCT07427134

• VV-14300: a gene therapy approach for adults with type 1 diabetes not well controlled on an automated insulin system

  This trial tests VV-14300 in adults with type 1 diabetes who aren’t reaching their blood sugar goals despite using an automated insulin delivery system.

  Recruiting Phase 1/2 Kriya Therapeutics, Inc. · Toronto and 1 other locations · NCT07831798

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.